Efficacy and Safety of a Lercanidipine/Enalapril Fixed-Dose Combination in Hypertensive Patients in Portugal

摘要

Background Fixed-dose combinations of hypertensive drugs have been advocated as a suitable option for hypertensive patients who require two or more drugs to achieve blood pressure (BP) targets. Objectives Our objective was to assess the efficacy and safety of lercanidipine/enalapril in clinical practice. Methods This observational study collected data for patients with hypertension treated by 46 specialists at clinics across Portugal with lercanidipine/enalapril (10/20?mg). The primary outcome measure was the reduction from baseline in systolic BP (SBP) and diastolic BP (DBP). Results The registry enrolled 315 patients (59.1?% females; mean age 64.84?±?12.18?years). Baseline SBP and DBP were 159.11?±?16.93 and 88.32?±?12.35?mmHg, respectively. At a mean 2.88?±?1.75?months after starting lercanidipine/enalapril, the mean change from baseline in SBP and DBP were ?18.08?±?15.91 and ?10.10?±?11.46?mmHg, respectively (both p Conclusions Treatment with the fixed-dose combination lercanidipine/enalapril was associated with significant reductions in SBP and DBP, and a significant increase in the BP control rate. This fixed-dose combination has been shown to effectively reduce BP, generally independently of age and sex, and with an excellent safety profile.